To the full analysis
Charles River Laboratories International stock: growth
CRLCharles River Laboratories International reported $4.02B in revenue for fiscal 2025, down 0.9% on the prior year, up 6.5% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
7.3%
per year from 2006 to 2025, per share 9.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.5% | 11.4% | 7.3% |
| Revenue per share | 6.5% | 10.7% | 9.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 6.4% | 8.8% | no data |
| Free cash flow per share | 6.4% | 8.1% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.06B | −$55.78M | −$17.38M |
| 2007 | $1.23B | $154.41M | $57.21M |
| 2008 | $1.34B | −$521.84M | $82.87M |
| 2009 | $1.2B | $114.44M | $145.03M |
| 2010 | $1.13B | −$336.67M | $126.15M |
| 2011 | $1.14B | $109.57M | $156.14M |
| 2012 | $1.13B | $97.3M | $160.37M |
| 2013 | $1.17B | $102.83M | $167.99M |
| 2014 | $1.3B | $126.7M | $194.13M |
| 2015 | $1.36B | $149.31M | $223.11M |
| 2016 | $1.68B | $154.77M | $243.03M |
| 2017 | $1.86B | $123.36M | $233.83M |
| 2018 | $2.27B | $226.37M | $301.09M |
| 2019 | $2.62B | $252.02M | $340.42M |
| 2020 | $2.92B | $364.3M | $380.02M |
| 2021 | $3.54B | $390.98M | $532.03M |
| 2022 | $3.98B | $486.23M | $294.91M |
| 2023 | $4.13B | $474.62M | $365.37M |
| 2024 | $4.05B | $10.3M | $501.61M |
| 2025 | $4.02B | −$144.34M | $518.49M |
Revenue by segment
How Charles River Laboratories International, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Discovery and Safety Assessment60%
- Research Models and Services21%
- Manufacturing Support19%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Discovery and Safety Assessment | $836.59M | $980.02M | $1.32B | $1.62B | $1.84B | $2.11B | $2.45B | $2.62B | $2.45B | $2.4B | 59.8% |
| Research Models and Services | $494.04M | $493.62M | $519.68M | $537.09M | $571.15M | $690.44M | $739.18M | $792.34M | $829.38M | $846.08M | 21.1% |
| Manufacturing Support | $350.8M | $383.96M | $429.56M | $465.14M | $515.35M | $742.49M | $789.57M | $721.44M | $769.33M | $766.41M | 19.1% |
| Total revenue | $1.68B | $1.86B | $2.27B | $2.62B | $2.92B | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B | 100% |
Revenue by region
Where Charles River Laboratories International, Inc. generates its revenue.
- United States53%
- Europe27%
- Canada12%
- Asia Pacific5%
- Other2%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| United States | $1.93B | $2.34B | $2.35B | $2.24B | $2.14B | 53.3% |
| Europe | $1.04B | $1.03B | $1.08B | $1.08B | $1.1B | 27.5% |
| Canada | $339.1M | $398.98M | $487.31M | $482.09M | $501.03M | 12.5% |
| Asia Pacific | $222.9M | $192.84M | $200.83M | $196.95M | $205.02M | 5.1% |
| Other | $0 | $0 | $0 | $52.82M | $64.87M | 1.6% |
| Total revenue | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 27 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.